We read with interest the report of WR Drobyski et al.
Diagnostic biopsies from the skin were consistent with the diagnosis of acute GVHD (Figure 1b) . Biopsies taken from the stomach, duodenum and colon were consistent with grade 4 GI GVHD (Figure 1c ). Liver biopsy also confirmed grade 4 hepatic GVHD.
A review of the patient's drug history did not reveal any likely culprits for a drug eruption, and her infectious workup was negative. Clinicopathologic correlation concluded that the most likely diagnosis was GVHD of the skin, GI tract and liver. Immunogenetic studies confirmed that the patient had indeed received autologous stem cell units.
Intravenous Ig and ganciclovir were discontinued, and systemic corticosteroids started. Following initiation of CYA, her skin cleared within 1 week, but large-volume diarrhea persisted. She also was treated with mycophenolate mofetil and infliximab, with no significant change in stool volume. She had a complicated course with worsening diarrhea, cholestasis and rash, followed by multiple episodes of sepsis, a fall resulting in a subdural hematoma requiring neurosurgical evacuation, and expiration due to overwhelming infection on day 162 post transplant.
Our review of the literature showed that 175 cases (including the five cases reported by Drobyski et al.) of 'autologous GVHD' have been reported to date with varying amounts of cutaneous, GI and hepatic involvement. Importantly, these cases were not CYA A-induced, and not transfusion-associated. These 175 cases include 136 post-auto-SCT cases, [1] [2] [3] [4] [5] [6] [7] [8] and 39 post-syngeneic SCT cases. 3, 9, 10 Overall, GVHD is thought to occur in roughly 5-20% of patients post-auto-SCT or syngeneic SCT. [2] [3] [4] Cutaneous involvement is most frequent, followed by intestinal involvement (13-20%), and liver (o1%). There are probably many more cases with subclinical disease. In one study by Hood et al., 3 of 115 patients status-post-auto-SCT, 7.8% showed clinical and histological cutaneous GVHD, and an additional 3.5% showed histological evidence but no clinical lesions. While it is hard to know whether a viral infection or drug reaction could have played a role in any of these cases, it is likely that GVHD occurs unrecognized in many patients.
Autologous GVHD has a milder course than allogeneic GVHD, and most patients resolve spontaneously. Several reported patients required corticosteroids and even fewer required CYA. Of 90 GI autologous GVHD cases in one series, 98% were classified as Grade 1 (2% Grade 3; 1 case Grade 4), and all patients responded to steroids. 4 Our case complements the five reported by Drobyski et al. 1 as it shows a severe, treatment-resistant presentation of GVHD in the auto-SCT setting. A notable feature of these six patients (our case and those of Drobyski et al. 1 ) is that all had multiple myeloma, and all developed severe life-threatening GVHD after auto-SCT. Notably, Drobyski et al. 1 found that the rate of developing GVHD following auto-SCT was 12% in patients who had undergone tandem SCTs, whereas it was only 0.9% in patients who had undergone single SCTs. Our case supports their finding 1 that the 'risk of developing autologous GVHD may be increased by the re-exposure to a second SCT'. Given that auto-SCT-associated GVHD is typically benign and selflimited, the severe presentations noted herein raise questions about how multiple myeloma or the drugs used to treat it may potentiate more severe GVHD. In contrast to the five reported cases of Drobyski et al., in which patients had two of three organ systems involved, our patient had GVHD affecting all three organ systems (cutaneous, GI and hepatic). Similar to the cases of Drobyski et al., our patient's condition did not respond to corticosteroids, and heavier immunosuppression including CYA, mycophenolate mofetil, corticosteroids and infliximab were required. Unfortunately, our patient succumbed to the condition, similar to four of the five cases reported by Drobyski et al.
